---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-115177"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:39:53.405353+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Taysha reports FY2025 net loss $109M; TSHA-102 pivotal trial dosing on track to complete Q2 2026

## Summary
- Net loss $109.0M ($0.34/share) vs $89.3M ($0.36) in 2024; R&D expenses rose to $86.4M.
- Cash $319.8M as of Dec 31, 2025; raised $50M via ATM in Q4; expects funding into 2028.
- Dosed multiple Rett patients in REVEAL pivotal trial; enrollment advancing, on track to complete dosing in Q2 2026.
- FDA cleared ASPIRE trial in patients aged 2 to <4 yrs; alignment on CMC and data pooling for BLA submission.
- TSHA-102 generally well tolerated; no treatment-related SAEs or DLTs as of March 2026 data cutoff.

## SEC filing metadata
- accession: 0001193125-26-115177
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/0001193125-26-115177-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-115177
- JSON: https://secwatch.observer/filing/0001193125-26-115177.json
- Plain text: https://secwatch.observer/filing/0001193125-26-115177.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.